Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib

机译：维拉非尼治疗BRAF（V600）突变的转移性皮肤黑色素瘤患者的皮肤毒性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionThe use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions.

机译：简介使用口服可用的BRAF激酶抑制剂-vemurafenib与许多不良皮肤反应有关。

著录项

期刊名称 Advances in Dermatology and Allergology/Postpy Dermatologii i Alergologii
作者
Elzbieta Nowara; Joanna Huszno; Grzegorz Slomian; Jaroslaw Nieckula;
展开▼
作者单位

展开▼
年(卷),期 2016(33),1
年度 2016
页码 52–56
总页数 5
原文格式 PDF
正文语种
中图分类皮肤病学与性病学;
关键词
cutaneous melanoma BRAF inhibitor vemurafenib skin toxicity;

机译：皮肤黑素瘤;BRAF抑制剂;维拉非尼;皮肤毒性;

相似文献

外文文献
中文文献
专利

1. Genomic Features of Exceptional Response in Vemurafenib +/- Cobimetinib-treated Patients with BRAF(V600)-mutated Metastatic Melanoma [J] . Yan Yibing, Wongchenko Matthew J., Robert Caroline, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第11期

机译：vemurafenib +/- cobimetinib治疗患者的特殊反应的基因组特征（v600） - 矫正转移黑色瘤
2. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF(V600) mutation-positive metastatic melanoma treated with vemurafenib +/- cobimetinib [J] . Lewis Karl, Hauschild Axel, Larkin James, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：用vemurafenib +/- cobimetinib处理的BRAF（v600）突变阳性转移性黑素瘤生存伴酸还原剂和vemureafenib剂量的疗效
3. Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience [J] . Arance A. M., Berrocal A., Lopez-Martin J. A., Clinical & translational oncology : . 2016,第11期

机译：维拉非尼在BRAF（V600）突变型转移性黑色素瘤患者中的安全性：西班牙的经验
4. Prediction of Metastatic Events in Patients With Cutaneous Melanoma [C] . Christian Scheibboeck, Patrick Huber, Stefanie Weber, International Conference on eHealth, Telemedicine, and Social Medicine . 2013

机译：皮肤黑素瘤患者转移事件预测
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study [O] . Lotte M. Knapen, Rutger H. T. Koornstra, Johanna H. M. Driessen, -1

机译：剂量和同时使用降酸剂对Vemurafenib在转移性BRAF V600突变性黑素瘤中的作用的影响：一项回顾性队列研究
7. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib [O] . Elzbieta Nowara, Joanna Huszno, Grzegorz Slomian, 2016

机译：用vemurafenib治疗的BRaF（V600）突变的转移性皮肤黑素瘤患者的皮肤毒性

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib

摘要

著录项

相似文献

相关主题

期刊订阅